4,901 trials
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 0 Participants
Schizophrenia
Primary: Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) — 5; 6; 9; 11 participants
Autoimmune Diseases · Fibrosis
Primary: Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV — 5.298; 5.857 Hours
Drug-drug Interaction · Autoimmune Diseases · Fibrotic Disease
Primary: Pharmacokinetics: Cmax of KD025 and KD025m2 in Part 1 — 1770; 2130; 227; 712 ng/mL
Hepatic Impairment · Hepatic Insufficiency · Healthy Subjects
Primary: Plasma Acalabrutinib PK Parameters — 1167; 226.1; 1161; 220.0 ng*hr/mL
Myeloma-Multiple · Myeloma, Plasma-Cell
Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…
Malaria,Falciparum · Parasitemia · Protozoan Infections
Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 4 Participants
Healthy Volunteers
Primary: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Mobocertinib — 6.01; 8.00 hours
Kidney Failure, Chronic · Renal Insufficiency
Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants
Chronic Kidney Disease
Primary: Metabolic Clearance of D6-25(OH)D3 — 360; 313; 263 milliliter per day (ml/d)
Bladder Cancer
Primary: Grade 3 or Higher Treatment Related Adverse Events as Assessed by CTCAE V5.0 — 0; 0.07 proportion of participants
Pharmacokinetic
Primary: Cmax — 508.6; 384.5; 289.5; 499.5 nmol/L
CNS Embryonal Tumor, Not Otherwise Specified · Malignant Glioma · Recurrent Atypical Teratoid/Rhabdoid Tumor
Primary: Maximum Tolerated Dose of Ribociclib and Everolimus — 120; 1.2 mg/m^2/day
Breast Cancer
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites at Each Treatment Period. — 64.85; 381.0; 138.2; 91.83 ng/mL